I think the omnitrope case was not a criticism of FDA. Perhaps FDA was pleased to have the court provide the interpretation of their review authority since it helped clear up the gray areas. I don't think the omnitrope matter hurt NVS' standing with FDA.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.